EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites37
Patients1128

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	591
New Zealand	210
Finland	127
Switzerland	59
Saudi Arabia	47
Belgium	43
Ireland	31
Slovenia	12
Germany	8
Total	1128